The FDA's Assessment of Two Drugs for Chronic Weight Management

Food and Drug Administration, Silver Spring, MD, USA.
New England Journal of Medicine (Impact Factor: 55.87). 10/2012; 367(17):1577-9. DOI: 10.1056/NEJMp1211277
Source: PubMed


Owing to a complex interplay among genetic, environmental, and cultural factors, obesity has reached epidemic proportions in the United States. The adverse health consequences of obesity are manifold, potentially involving all major organ systems and contributing to reduced quality of life. The goal of all obesity therapies is negative energy balance. Drugs have long been used in an attempt to achieve this goal. However, numerous once-promising weight-loss drugs have been abandoned because of serious toxic effects: aminorex (which caused pulmonary hypertension), fenfluramine and dexfenfluramine (valvulopathy), phenylpropanolamine (stroke), rimonabant (suicidal ideation and behavior), and most recently sibutramine (myocardial infarction and stroke). . . .

11 Reads
  • Source
    • "(1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine [lorcaserin (Belviq ® ; Arena Pharmaceuticals, San Diego, CA)] (Smith et al., 2008) was recently approved by the U.S. Food and Drug Administration for treating obesity (Colman et al., 2012). The therapeutic effects of lorcaserin are thought to be due to agonist activity at serotonin (5-HT) 2C receptors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lorcaserin is approved by the Food and Drug Administration for treating obesity and its therapeutic effects are thought to result from agonist activity at serotonin (5-HT)2C receptors. Lorcaserin has affinity for other 5-HT receptor subtypes, although its activity at those subtypes is not fully described. The current study compared the behavioral effects of lorcaserin (0.0032-32.0 mg/kg) to the effects of other 5-HT receptor selective agonists in rats (n=8). The 5-HT2C receptor selective agonist mCPP (0.032 - 1.0 mg/kg) and lorcaserin induced yawning that was attenuated by the 5-HT2C receptor selective antagonist SB 242084 (1.0 mg/kg). The 5-HT2A receptor selective agonist DOM (0.1-3.2 mg/kg) induced head twitching that was attenuated by the 5-HT2A receptor selective antagonist MDL 100907 (0.01 mg/kg), lorcaserin (3.2 mg/kg), and mCPP (3.2 mg/kg). In rats pretreated with 5-HT2C SB 242084 (1.0 mg/kg), lorcaserin also induced head twitching. At larger doses, lorcaserin produced forepaw treading that was attenuated by the 5-HT1A receptor selective antagonist WAY 100635 (0.178 mg/kg). While the behavioral effects of lorcaserin in rats are consistent with it having agonist activity at 5-HT2C receptors, these data suggest that, at larger doses, it also has agonist activity at 5-HT2A and possibly 5-HT1A receptors. Mounting evidence suggests that 5-HT2C receptor agonists might be effective for treating drug abuse. A more complete description of the activity of lorcaserin at 5-HT receptor subtypes will facilitate a better understanding of the mechanisms that mediate its therapeutic effects.
    Journal of Pharmacology and Experimental Therapeutics 09/2015; DOI:10.1124/jpet.115.228148 · 3.97 Impact Factor
    • "Clinical studies involving overweight and obese individuals with one obesity-related comorbidity have shown modest weight reduction of ~ 5% [95]. On the up side, the drug has shown a relatively good tolerability profile and the increased incidence of valvulopathy observed in rodents has not been borne out in humans thus far [94]. Phentermine, a central noradrenaline releasing drug and topiramate, is a licensed antiepileptic drug. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is on the rise and the pursuit of efficient and safe treatment is ongoing. Available anti-obesity medical therapies have so far proved to be disappointing, whereas bariatric surgery is leading the way and offers long-term health benefits. Part of the success of bariatric surgery is thought to be mediated by gut hormones. A better understanding of the role of gut hormones within the gut-brain signaling pathway in the control of hunger, satiety, and energy homeostasis, has led to their therapeutic exploitation as possible anti-obesity drugs. In this review, we provide a summary of currently available treatment options for obesity from simple lifestyle modifications and bariatric surgery to traditional and novel medical therapies.
    Postgraduate Medicine 06/2015; 127(5):494-502. DOI:10.1080/00325481.2015.1048181 · 1.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oral lorcaserin (Belviq®), a novel selective serotonin 5-HT2C receptor agonist, is indicated in the USA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults, or overweight adults with at least one weight-related co-morbidity. In 12-month clinical studies, lorcaserin was more effective than placebo in reducing weight in obese or overweight adults with or without type 2 diabetes mellitus. It is well tolerated and does not appear to be associated with an increased risk of valvulopathy.
    Drugs & Therapy Perspectives 10/2013; 29(10). DOI:10.1007/s40267-013-0056-6
Show more


11 Reads
Available from